The Kidney-Heart Connection in Women: What the eGFR Misses

The kidney-heart axis is bidirectional. Failing kidneys accelerate cardiovascular disease, and failing hearts damage kidneys. This relationship is well-established in the literature and taught in every cardiology fellowship. What receives far less attention is that in women, this relationship has additional sex-specific layers that alter how CKD presents, how it is detected, and how aggressively it must be managed before the cardiovascular consequences become irreversible.

Women with chronic kidney disease develop cardiovascular complications at different rates and through different pathways than men. Preeclampsia, a condition exclusive to pregnancy, accelerates CKD progression by decades. Lupus nephritis, which overwhelmingly affects women in their reproductive years, creates a fast track to kidney failure and cardiovascular mortality. And the most widely used test for kidney function, the creatinine-based estimated glomerular filtration rate, systematically underestimates kidney disease severity in women with low muscle mass. Understanding these three layers is essential for any clinician managing women’s cardiovascular risk.

The Creatinine Trap

The estimated glomerular filtration rate (eGFR) is the standard clinical measure of kidney function. It estimates how well the kidneys filter blood by measuring serum creatinine, a byproduct of creatine phosphate metabolism in muscle. The key word is muscle. Creatinine production is proportional to muscle mass, and muscle mass varies substantially between individuals and between sexes.

Women have lower muscle mass than men at equivalent body size and equivalent kidney function. A woman with a genuinely reduced GFR of 55 mL/min may produce so little creatinine that her serum level looks reassuringly normal, and her calculated eGFR appears higher than her actual kidney function. This is not a minor rounding error; it can shift a patient’s CKD staging by a full category.

The CKD-EPI 2021 equation, the current standard for eGFR calculation, uses sex-specific creatinine thresholds to partially correct for this difference. For women the threshold is set at 0.7 mg/dL; for men at 0.9 mg/dL. This adjustment helps in average women but breaks down at the extremes: elderly women, frail women, underweight women, and women with muscle-wasting conditions may have creatinine levels so low that even the sex-adjusted equation overestimates their GFR.

An alternative marker, cystatin C, is produced by all nucleated cells at a relatively constant rate regardless of muscle mass or sex. Cystatin C-based eGFR is more accurate in populations with low muscle mass and is now recommended when creatinine-based eGFR appears discordant with the clinical picture. If a woman has nephrotic-range proteinuria, hypertension that is difficult to control, or symptoms suggesting uremia but her creatinine-based eGFR reads as normal or mildly reduced, cystatin C measurement is indicated. Current guidelines support combining both markers in an eGFRcr-cys equation for improved accuracy in ambiguous cases.

The cardiovascular stakes of missing early CKD are substantial. A landmark analysis of over one million adults in Kaiser Permanente established that eGFR below 60 mL/min per 1.73 m2 carries significantly elevated cardiovascular event risk across both sexes, with risk escalating steeply as GFR falls below 45 and again below 30.

Each CKD stage carries additive risk through multiple mechanisms: accelerated atherosclerosis from uremic toxins, hypertension from salt and water retention, dyslipidemia with elevated triglycerides and reduced HDL, anemia that places additional metabolic demands on the heart, and mineral-bone disorder that drives vascular calcification. In women whose CKD is underestimated, these processes advance in the background while clinical attention is directed elsewhere.

Pregnancy History as Kidney History

Preeclampsia is commonly framed as a pregnancy complication that resolves at delivery. Blood pressure normalizes over weeks, proteinuria clears, and the patient is discharged with instructions to follow up with her obstetrician. What she is rarely told is that preeclampsia leaves a biological signature in her kidneys that may not manifest as detectable CKD for one to two decades but substantially accelerates the timeline when CKD eventually develops.

The mechanism is endothelial dysfunction and glomerular injury sustained during the preeclamptic episode. The placenta in preeclampsia releases anti-angiogenic factors, particularly sFlt-1, that damage systemic and renal endothelium. Glomerular capillary endotheliosis, the pathological hallmark of preeclampsia found on renal biopsy, represents genuine structural injury. When proteinuria resolves after delivery, the visible marker has cleared, but the underlying capillary damage has not fully healed. The glomeruli are left with reduced functional reserve.

A Norwegian registry study following over 570,000 women over a median of more than 17 years found that women with a history of preeclampsia had a significantly elevated risk of developing end-stage renal disease requiring dialysis or transplantation compared to women with uncomplicated pregnancies. The relative risk was most elevated for preeclampsia in multiple pregnancies and for severe or early-onset preeclampsia.

Women who had gestational hypertension without proteinuria also showed elevated ESRD risk, though lower than those with frank preeclampsia. This is clinically important because gestational hypertension is often viewed as a lesser condition; the renal implications suggest it still warrants longitudinal follow-up.

The obstetric discharge moment represents a missed screening opportunity that recurs every time these women present to any clinician. A woman who had preeclampsia at age 28 and presents to a cardiologist at age 50 with hypertension is unlikely to have her obstetric history reviewed in the context of her current renal function. Yet her preeclampsia history changes the calculus of how aggressively her blood pressure should be controlled and how frequently her renal function should be monitored.

For women with a history of preeclampsia, some cardiologists recommend annual eGFR and urine albumin-to-creatinine ratio (ACR) monitoring starting within five years of the index pregnancy, escalating to more frequent monitoring if ACR rises above 30 mg/g. Urine ACR provides early warning of glomerular damage at a stage where eGFR is still preserved; it should not be omitted in favor of creatinine alone.

Lupus and the Fast Track to CKD

Systemic lupus erythematosus affects women at a 9:1 ratio to men, with onset concentrated in the reproductive years between ages 15 and 45. Lupus nephritis, caused by immune complex deposition in glomerular capillaries, occurs in 50 to 60 percent of SLE patients at some point in their disease course. In patients with diffuse proliferative lupus nephritis (class III or IV by WHO classification), GFR decline can be rapid over months without aggressive immunosuppression.

Even women with controlled lupus nephritis carry substantially elevated cardiovascular risk that extends far beyond what their kidney function alone would predict. SLE patients have 2 to 10 times higher cardiovascular mortality than age-matched controls, depending on the study population and follow-up duration. This excess risk comes from multiple intersecting pathways: the inflammatory burden of SLE itself (elevated complement activation, anti-double-stranded DNA antibodies, persistently elevated CRP) accelerates atherosclerosis independently of CKD. Corticosteroids used to treat lupus contribute to hypertension, dyslipidemia, and glucose intolerance. Hydroxychloroquine, the cornerstone of SLE maintenance therapy, has some cardioprotective properties through lipid and platelet effects, but its protective signal does not fully offset the disease-related risk.

Belimumab, a monoclonal antibody targeting BAFF (B-lymphocyte stimulator), has shown nephroprotective signals in recent trials, including delay to renal flare and reduction in proteinuria in active lupus nephritis. Whether this translates to long-term reduction in cardiovascular events through preserved renal function is an active area of investigation.

For cardiologists managing women with SLE, renal function is not an ancillary test. It is a core cardiovascular risk marker. Routine monitoring of eGFR, urine ACR, and blood pressure at each cardiology visit is appropriate. Urine ACR elevation that precedes GFR decline may represent early glomerular injury from a lupus flare that has not yet been recognized, and its detection can prompt rheumatology referral before GFR is lost.

SGLT2 Inhibitors: The Renal Evidence

The emergence of sodium-glucose cotransporter-2 (SGLT2) inhibitors as nephroprotective agents is one of the most significant developments in CKD management in a generation. The mechanism involves multiple convergent pathways: tubuloglomerular feedback restoration (reducing glomerular hyperfiltration), direct anti-inflammatory and anti-fibrotic effects on the tubulointerstitium, reduction in intraglomerular pressure, and natriuresis that reduces blood pressure and volume load on both the heart and kidney.

The CREDENCE trial tested canagliflozin against placebo in 4,401 patients with type 2 diabetes and CKD, defined by eGFR of 30 to 90 mL/min per 1.73 m2 and albuminuria above 300 mg/g. The trial was stopped early at a median follow-up of 2.6 years because canagliflozin reduced the primary composite renal endpoint (doubling of serum creatinine, end-stage kidney disease, or renal or cardiovascular death) by 30 percent. This was a pre-specified primary endpoint, not a secondary signal.

The DAPA-CKD trial extended the benefit beyond diabetic kidney disease. Dapagliflozin was tested in 4,304 patients with CKD (eGFR 25 to 75) with or without type 2 diabetes. The 39 percent reduction in the composite renal and death outcome was consistent across the diabetic and non-diabetic subgroups, establishing that the renal protection is not glucosuria-dependent. Sex-disaggregated analyses of both CREDENCE and DAPA-CKD showed consistent benefit in women, with no significant interaction by sex.

SGLT2 inhibitors are also particularly relevant to women because they reduce hospitalization for heart failure with preserved ejection fraction (HFpEF), which is the dominant heart failure phenotype in women, especially postmenopausal women with CKD. The EMPEROR-Preserved trial demonstrated that empagliflozin reduced cardiovascular death and HF hospitalization in HFpEF across both sexes. Women with CKD who develop HFpEF, a common intersection, receive simultaneous nephroprotective and cardiac benefit from SGLT2 inhibition.

Clinicians should counsel patients that an initial eGFR dip of 3 to 5 mL/min when starting an SGLT2 inhibitor is expected and represents a hemodynamic effect from reduced glomerular pressure, not nephrotoxicity. The drug should not be discontinued for this transient change, as the long-term eGFR trajectory is favorable.

ACE Inhibitors, ARBs, and Women

Both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce proteinuria and slow CKD progression through blockade of the AT1 receptor, which mediates efferent arteriolar vasoconstriction and glomerular hyperfiltration. They carry a Class I indication for proteinuric CKD in current guidelines regardless of whether hypertension is present.

Women tolerate these agents somewhat differently than men, and the differences are clinically actionable. ACE inhibitor-induced cough occurs in 10 to 15 percent of women compared to approximately 5 percent of men. The mechanism is bradykinin accumulation: ACE inhibitors block the degradation of bradykinin, which then activates sensory nerve fibers in the airway. ARBs do not increase bradykinin and do not cause this cough. When a woman with proteinuric CKD develops ACE inhibitor-induced cough, switching to an ARB is appropriate and preserves full nephroprotection without compromising efficacy.

Combination ACE inhibitor plus ARB therapy was tested in the ONTARGET trial and found to increase hyperkalemia and acute kidney injury without providing additional renal or cardiovascular benefit compared to either agent alone. Dual renin-angiotensin-aldosterone system blockade is not recommended in CKD.

Potassium monitoring is required with all RAAS-blocking agents, particularly in CKD stage 3b and 4 where urinary potassium excretion is already reduced. Women with lower baseline serum potassium may appear to tolerate RAAS blockers with more safety margin initially, but the risk of hyperkalemia rises steeply as eGFR falls below 30 and remains a reason for monitoring rather than complacency. New potassium binders (patiromer, sodium zirconium cyclosilicate) have expanded the ability to maintain RAAS blockade in CKD patients who develop mild to moderate hyperkalemia, avoiding premature discontinuation.

Cardiorenal Syndrome in HFpEF

Heart failure with preserved ejection fraction is the dominant heart failure phenotype in women, and it carries a high likelihood of concurrent CKD. The intersection of the two creates a particular management challenge: the kidney disease limits fluid clearance, worsening heart failure; the heart failure elevates venous pressure, which is then transmitted backward to the kidneys and reduces GFR through a mechanism distinct from reduced cardiac output.

This backward transmission of elevated venous pressure, cardiorenal syndrome type 2, was initially underappreciated as a driver of renal dysfunction in heart failure. Studies using right heart catheterization demonstrated that elevated central venous pressure independently predicts worsening renal function in decompensated heart failure, above and beyond the contribution from reduced cardiac output. Renal venous congestion physically impedes glomerular filtration by reducing the pressure gradient across the Bowman’s capsule.

The clinical implication is that aggressive diuresis to reduce venous pressure often improves rather than worsens renal function in congested HFpEF patients, even when creatinine rises transiently in the first 48 to 72 hours. Women with HFpEF who develop worsening renal function during hospitalization warrant careful assessment of volume status before diuretics are held. The assumption that rising creatinine means the kidneys cannot tolerate diuresis is often incorrect in the context of persistent venous congestion.

The EMPEROR-Preserved trial data are relevant here as well. Empagliflozin reduced the composite primary endpoint and had renal protective signals in the HFpEF population, providing an option that addresses both conditions simultaneously in women with this common phenotype.

Anemia, AKI Risk, and Procedures

Women have lower baseline hemoglobin than men, with normal ranges reflecting this difference (12 to 16 g/dL for women, 13.5 to 17.5 g/dL for men). In CKD, reduced erythropoietin production from the damaged kidney causes normocytic anemia that becomes symptomatic earlier in women because their baseline is already lower.

Erythropoiesis-stimulating agents are indicated for CKD-related anemia but the TREAT trial established that targeting hemoglobin above 13 g/dL in CKD patients increases cardiovascular event risk, particularly stroke. Current guidelines target hemoglobin between 10 and 11.5 g/dL for most CKD patients on ESA therapy. Iron deficiency is extremely common in CKD anemia and is particularly prevalent in premenopausal women who lose iron monthly. Evidence favors intravenous iron supplementation over ESA dose escalation when ferritin is below 200 ng/mL or transferrin saturation is below 20 percent, as IV iron is more effective, avoids ESA-related cardiovascular risks, and does not require injections at every visit once a repletion course is complete.

Contrast-induced acute kidney injury is a procedural risk that deserves specific attention in women undergoing cardiac catheterization. The evidence shows women face higher contrast-induced AKI risk than men with equivalent CKD, attributable to smaller vessel caliber requiring longer procedure times, potentially higher contrast volumes relative to kidney mass, and sometimes less aggressive pre-procedural hydration when clinical teams underestimate CKD severity from creatinine-based eGFR alone.

Pre-procedural hydration with isotonic saline should be applied consistently to women with eGFR below 60 undergoing contrast procedures. Because creatinine-based eGFR may underestimate CKD in small or elderly women, consideration of cystatin C measurement in the weeks before elective cardiac catheterization provides better risk stratification and may trigger more protective hydration protocols.

Synthesis: Sex-Specific Layers of the CKD-CVD Overlap

The cardiorenal syndrome in women is not simply the male version with different numbers. The pathways are different, the timelines are different, and the screening triggers are different. A woman who had preeclampsia in her twenties, developed subclinical lupus nephritis in her thirties, and presents to cardiology in her fifties with hypertension and mild eGFR reduction has accumulated decades of renal endothelial injury through pathways that male-dominated cardiology literature barely registers.

Three clinical practices follow directly from the evidence. First, eGFR should not be interpreted from creatinine alone in women with low muscle mass; cystatin C provides a more accurate picture, and the combined eGFRcr-cys equation should be used when there is clinical discordance. Second, obstetric history should be standard in the cardiovascular risk assessment of women: preeclampsia, gestational hypertension, and lupus nephritis during pregnancy represent renal risk exposures that carry decades-long cardiovascular implications. Third, SGLT2 inhibitors now represent a first-line nephroprotective option in proteinuric CKD regardless of diabetes status, and the sex-disaggregated trial data support their use in women without reservation.

The bidirectionality of the kidney-heart relationship means that every decision made in cardiology has a renal consequence, and every decision made in nephrology has a cardiac consequence. In women, additional sex-specific pathways multiply the opportunities to intervene early and multiply the consequences of missing those opportunities. The tools to identify high-risk women are available. The evidence for intervention is strong. The gap is awareness and systematic incorporation of pregnancy history, autoimmune history, and refined GFR measurement into routine cardiovascular care.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.